Remedies › IP6 › Heart-valve and artery calcification · All remedies for heart-valve and artery calcification
IP6 and heart-valve and artery calcification: what the evidence says
Small or mixed human studies suggest IP6 may slow calcium build-up in heart valves and arteries, but the trials used an intravenous drug form, not oral supplements.
3/5 LimitedSome human evidence: small trials, trials on a related outcome, or population studies that disagree. How we score
This is the strongest human evidence anywhere on IP6-type compounds, and it is filed under a drug code, SNF472, rather than under IP6. SNF472 is the hexasodium salt of IP6, developed by Sanifit Therapeutics, a company that grew out of the University of the Balearic Islands group that also published much of the kidney-stone research.
In a randomized trial of 274 people on dialysis, SNF472 given by vein three times a week slowed the growth of calcium in the coronary arteries (11% vs 20% with placebo) and the aortic valve (14% vs 98%) over a year.
A later randomized phase 3 trial in 71 people with calciphylaxis, a painful calcium disease of the skin, found no benefit on wound healing, and pain improved more with placebo. An earlier uncontrolled study of 14 patients had looked strongly positive, which is a reminder of why controlled trials matter.
None of this was tested with oral IP6 supplements, which are absorbed very differently, so these results cannot be carried over to a capsule.
- Meta-analyses of trialspooled randomized trials0
- Human studiestrials and population studies3
- Case reportssingle people0
- Animal studiesmostly rodents0
- Lab studiescells, test tubes0
The studies in people, read one by one
| Result | Type | What they did | What they found |
|---|---|---|---|
| Positive | Randomized trial, 2020 274 people | Randomized, placebo-controlled phase 2b (CaLIPSO), intravenous SNF472 during dialysis for 52 weeks Measured: Growth of coronary artery and aortic valve calcium | Coronary calcium volume grew 11% vs 20% with placebo (p = 0.016); aortic valve 14% vs 98% (p < 0.001); thoracic aorta no difference (p = 0.40). PubMed 31707860 |
| No effect | Randomized trial, 2024 71 people | Randomized, placebo-controlled phase 3 (CALCIPHYX), intravenous hexasodium fytate in calciphylaxis Measured: Wound healing and pain at 12 weeks | No difference in wound score (p = 0.88); pain fell 19.5 points vs 32.2 with placebo (p = 0.15), per the trial's posted results. PubMed 39252867 |
| Positive | Population study, 2015 188 people | Cross-sectional study of elderly outpatients, Mallorca Measured: Heart-valve calcification vs urine phytate | People with higher urinary phytate had less mitral annulus calcification; a snapshot, so it cannot show cause. PubMed 26322979 |
Where the sources agree, and where they don’t
2 of 4 kinds of source point toward a benefit, 1 toward no effect or harm, 0 are mixed, and 1 has no data yet. Agreement between independent kinds of evidence matters more than the number of papers in any one of them.
| Kind of source | Points to | Detail |
|---|---|---|
| Randomized trial (IV drug form) | Positive | slower coronary and valve calcium |
| Phase 3 trial (IV drug form) | No effect | calciphylaxis wounds and pain |
| Population study | Positive | higher urine phytate, less valve calcium |
| Oral supplement trial | No data | registered 2009, never reported |
Beyond Google: 6 findings about IP6 from trial registries, FDA reports and patent offices that a normal search rarely shows. See them
What people report
None of the 41 public reports we read so far were about this condition. See all reports on the IP6 page.
Every other paper we found
PubMed lists – papers for this search. We have read the human trials above; the rest are mostly lab studies of the same combination.
Other conditions IP6 has been studied for
- IP6 and cancer 2/5 Preliminary
- IP6 and chemotherapy side effects 3/5 Limited
- IP6 and kidney stones 3/5 Limited
Checked against PubMed on 2026-10-27. Everything we know about IP6